Vectibix fails pivotal trial in head and neck cancer
This article was originally published in Scrip
Executive Summary
Amgen's EGFR-targeted monoclonal antibody drug Vectibix (panitumumab) has failed to improve overall survival in its pivotal Phase III trial in advanced head and neck cancer.